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Abstract
Background: Previous research found an association of CRP with QT time in population based samples. Even more, there is
evidence of a substantial involvement of the tumor necrosis factor-alpha system in the pathophysiology of cardiac
arrhythmia, while the role of Interleukin 6 remains inconclusive.
Objective: To determine the association between inflammation with an abnormally prolonged QT-time (APQT) in men and
women of the elderly general population.
Methods: Data descend from the baseline examination of the prospective, population-based Cardiovascular Disease, Living
and Ageing in Halle (CARLA) Study. After exclusion of subjects with atrial fibrillation and missing ECG recording the final
study cohort consisted of 919 men and 797 women. Blood parameters of inflammation were the soluble TNF-Receptor 1
(sTNF-R1), the high-sensitive C-reactive protein (hsCRP), and Interleukin 6 (IL-6). In accordance with major cardiologic
societies we defined an APQT above a QT time of 460 ms in women and 450 ms in men. Effect sizes and the corresponding
95% confidence intervals (CI) were estimated by performing multiple linear and logistic regression analyses including the
analysis of sex differences by interaction terms.
Results: After covariate adjustment we found an odds ratio (OR) of 1.89 (95% CI: 1.13, 3.17) per 1000 pg/mL increase of
sTNF-R1 in women, and 0.74 (95% CI: 0.48, 1.15) in men. In the covariate adjusted linear regression sTNF-R1 was again
positively associated with QT time in women (5.75 ms per 1000 pg/mL, 95% CI: 1.32, 10.18), but not in men. Taking possible
confounders into account IL-6 and hsCRP were not significantly related to APQT in both sexes.
Conclusion: Our findings from cross-sectional analyses give evidence for an involvement of TNF-alpha in the pathology of
APQT in women.
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Introduction
A prolonged QT time is one of the most important electrocar-
diographic abnormalities, and an important cause of sudden
cardiac death [1]. Because the QT time is generally longer in
females, women are more often affected by arrhythmia due to a
prolonged QT interval than men [2]. Over the last decades,
research has mainly revealed insights in the genetic pathogenesis of
a prolonged QT time [3]. However, the meaning of further
pathophysiological mechanisms in the development of this
abnormality is still the subject of research. In particular, the role
of inflammation parameters and cytokines has rarely been
examined. To our knowledge, there are only a few studies
examining the association of inflammation and QT time [4,5]. In
a population-based sample, Kim et al. found a positive association
of increased blood level of C-reactive protein (CRP) and length of
the heart rate-corrected QT time (QTc). This is similar to the
results in Kazumi et al. [4], who revealed again a significant
association of CRP and QTc in a cohort of young healthy men.
While the above-mentioned studies focused mainly on CRP, data
examining additional inflammation parameters are still missing.
Notably, the soluble tumor necrosis factor receptor 1 (sTNF-R1)
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might serve as a promising parameter as it was revealed that
sTNF-R1 is a strong predictor for cardiovascular survival [6,7]. In
experimental studies, the TNF-alpha system – whose activity can
be assessed by the plasma level of sTNF-R1 [8]– was found to
influence calcium [9,10] and potassium [11,12] channels affecting
QT time (shortening for the former and prolongation for the latter)
and the susceptibility to arrhythmia [13]. The stability of sTNF-
R1 makes it an easily assessable marker of the larger TNF system
[14]. Furthermore, there is evidence from previous studies that
interleukin 6 (IL-6) plays a major in role in the pathophysiology of
cardiac arrhythmia [15,16].
As prolonged QT time remains often undetected in apparently
healthy subjects, it is typically a condition most relevant in
(healthy) subjects of the general population, rather than patients in
a clinical setting. Thus, the goal of the current study was to analyze
the association between inflammation parameters, especially
sTNF-R1, and prolonged QT time in the general population.
Methods
Study cohort
We used data from the CARdio-vascular Disease, Living and Ageing
in Halle study (CARLA study), which is a prospective population-
based cohort study of the elderly general population of the city of
Halle in eastern Germany [17,18]. The CARLA cohort comprises
1,779 participants (baseline response 64.1%) aged 45–83 years at
baseline (812 women, 967 men). The baseline examination took
place between December 2002 and January 2006. A multi-step
recruitment strategy aimed to achieve a high response rate. The
percentage final response after subtracting exclusions (individuals
who were deceased prior to the invitation, had moved away, or
were unable to participate due to illness) was 64%. All data used in
this cross sectional analysis descend from the baseline examination
of the study. The study participants underwent a detailed medical
examination and a standardized, computer-assisted interview,
which collected information on socio-demographic and socioeco-
nomic variables, behavioral, biomedical, and psychosocial factors,
medical history, and the use of medication within the preceding 7
days. Medication was automatically coded according to the
Anatomical Therapeutic Chemical Classification System (ATC
code). Additionally, an analysis of non-respondents was performed
in order to assess non-response bias by obtaining information
about prevalent diseases, and selected behavioral and socio-
demographic factors. A more comprehensive account of the
CARLA study can be found in Greiser et al. [17]. The study was
approved by the Ethics Committee of the Medical Faculty of the
Martin-Luther-University Halle-Wittenberg and by the State Data
Privacy Commissioner of Saxony-Anhalt and conformed to the
principles outlined in the Declaration of Helsinki [19]. All
participants gave written informed consent.
Subjects with electrocardiographic signs (n = 44) of atrial
fibrillation assessed by Minnesota code [20] and a senior
cardiologist were excluded.
Laboratory measurements
Blood samples were taken after a supine rest of 30 minutes. The
inflammation parameters of sTNF-R1 and IL-6 were analyzed by
the Department of Medicine III, University Clinics Halle (Saale).
After a 10-min centrifugation (20uC, 1,500 rpm, Acc = 9, Dcc = 3),
the plasma was collected and stored at280uC. The cytokines were
determined using commercially available sandwich enzyme-linked
immunosorbent assays (ELISAs: IL-6, Opteia, BD Biosciences,
Heidelberg, Germany; TNF-R1, Boehringer Mannheim, Mann-
heim, Germany).
The determination of CRP was undertaken by the Institute of
Laboratory Medicine, Clinical Chemistry and Molecular Diag-
nostics at the Leipzig University Clinics. The laboratory has been
accredited according to the accreditation norms ISO 15180 and
ISO 17025. Serum levels of high-sensitivity CRP (hsCRP) were
measured using a high-sensitivity immunoturbidimetric method
(CRP [Latex] HS, Roche, Mannheim, Germany) on a Hitachi
autoanalyzer (Roche Diagnostics, Mannheim, Germany).
Electrocardiogram (ECG) recoding
12-lead ECGs after a supine resting period of at least 20 min
were recorded for 10 seconds (sec). All ECGs were processed by
the Modular ECG Analysis System (MEANS) [21] to obtain the
locations and types of the QRS complexes, and to assess the QT
time in the 10-sec ECG. After detecting and, if possible, correcting
artefacts by using an algorithm, the program takes all 12 leads into
account and computes the QT time from a characteristic beat
after considering further beats by an averaging process. Estab-
lished as an objective method to assess peaks and intervals in
ECGs previous studies ascertained the sufficient performance of
the MEANS algorithm [22,23]. In an independent test sample the
algorithm identified all QRS (dominant type) complexes correctly
(one false positive). Evaluating the accuracy of waveform
recognition the difference in QT interval duration between
MEANS and a reference standard was less than 2 ms with low
variation [23].
We corrected the QT (QTc) time for heart rhythm by using the
Bazett-Formula [24].
Statistical analysis
According to the recommendations of major cardiologic
scientific societies [25], we assumed an abnormally prolonged
QT time (APQT) when the QTc was longer than 450 ms in men
and longer than 460 ms in women [26]. In this article, we use the
term ‘abnormally prolonged QT time’ rather than ‘long QT
syndrome’, as the latter sometimes refers to underlying genetic
abnormalities. Since the heart rate corrected QT time is computed
using the uncorrected QT time and the recorded heart rate (HR)
we included both parameters additionally in our analyses. All
analyses were separately performed in men and women. Using
logistic regression analyses with the binary outcome of existing
APQT odds ratios with 95% confidence intervals (CI) were
estimated as unadjusted and covariate adjusted values. Sex
differences in the association of inflammation and QTc were
assessed by incorporating an interaction term in the regression
models. Non-linearity was assessed using restricted cubic splines
which indicated that the assumption of linearity was a sufficient
approximation of the exposure-outcome relation [27]. We used
linear regression models (unadjusted and adjusted) in the analyses
of QTc, QT and HR now as continuous variables. Respecting
previous findings [5,28], we adjusted our analyses for age, anti-
arrhythmic (ATC code: C01B) and anti-phlogistic medication
(ATC code: A07), current smoking status, high density lipoprotein
(HDL), cholesterol, glucose blood level, alcohol intake, body mass
index, thyroid stimulating hormone (TSH), systolic blood pressure,
and potentially QT prolonging drugs (see www.qtdrugs.org) after
reevaluating possible confounders by using directed acyclic graphs
(DAG) [29]. With the assumed DAG model (see Figure S1) it is
possible to estimate the total effect of inflammation on QTc.
However, as mediation by electrolytes (not assessed in our study) is
likely the direct effect cannot be estimated [30–32].
The adequacy of the considered regression models was assumed
when the residuals were normally distributed, which was tested via
a Q-Q plot and Cook’s distance, which was required to be below
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one. In order to avoid possible confounding due to hormonal
influences in females [33], we performed a sensitivity analysis
excluding all premenopausal female subjects (n = 58, self-reported)
and women with self-reported intake of sexual hormones
(estrogens or gestagens) on a regular basis (n = 28) (detailed results
are displayed in the supporting information). Additionally we
performed a sensitivity analysis where all subject (120 men and 93
women) with regular intake of potentially QT prolonging drugs
(see www.qtdrugs.org) were excluded from the analysis (detailed
results are displayed in the supporting information).
The limit of statistical significance was assumed at an a of 5%.
All statistical analyses and data management were performed
using SAS, Version 9.3 (SAS Inc., Cary, NC, USA).
Missing values
The following parameters incorporated in our analysis con-
tained missing values (the number of missing values is given in
brackets): IL-6 (121), hsCRP (82), sTNF-R1 (123), QTc (19),
thyroid-stimulating hormone (21), glucose (12), cholesterol (12),
HDL (12), triglycerides (12), current alcohol intake (3), and current
smoking status (1). All other parameters were measured in all
subjects. Using Student’s t-Test and Chi-Square Test, we found no
statistically significant differences when the mean values or
frequencies, respectively, of the considered covariates (age, anti-
arrhythmic [ATC code: C01B] and anti-phlogistic medication
[ATC code: A07], current smoking status, HDL, cholesterol,
glucose blood level, alcohol intake, and atrial fibrillation) were
compared between subjects with missing inflammation parameters
or QTc and subjects with complete data. As there were few
missing values (maximum: 6.97% missing, sTNF-R1) and no
evidence of bias or confounding due to incomplete data was
evident, we conducted a complete case analysis.
Results
Baseline characteristics
Out of the 1,716 subjects with measured QT time, 123 (13.3%)
men and 75 (9.4%) women showed a prolonged QTc according to
our definition. Focusing on the inflammation parameters, plasma
levels were homogenous between male and female subjects; only in
the case of sTNF-R1 men showed higher plasma levels than
women (see Table 1). Male subjects with APQT had only slightly
higher blood values of sTNF-R1 than men without APQT.
However, in female subjects with APQT, we found considerably
higher sTNF-R1 plasma levels compared with women without
such an electrocardiographic characteristic. The mean values of
the inflammation parameter of IL-6 were lower in subjects without
APQT then in subjects with APQT. In female and male subjects,
hsCRP was higher in the APQT group than in the group with
normal QTc (see Table 1). Out of the parameters taken as
covariates into account, BMI appeared to be higher in the APQT
subgroups of both sexes.
In men, 25 (20.3%) of the subjects with a APQT received
potentially QT prolonging drugs (Table 1), while the proportion
was distinctly lower in women (13.3%).
Table 1. Baseline characteristics of the CARLA collective – differentiated according to sex and presence of prolonged QT time.
Men QTc , 450 ms Men QTc . 450 ms p{
Women QTc ,
460 ms Women QTc . 460 ms p{
[95% CI] [95% CI] [95% CI] [95% CI]
N* 796 (46,4%) 123 (7,2%) - 722 (42.1%) 75 (4,4%) -
cQT [ms] 417.79 [416.52, 419.07] 468.8 [465.85, 471.78] - 423.11 [421.77, 424.46] 476.48 [473.03, 479.95] -
sTNF-R1 [pg/mL] 1159.85 [1129.41,
1191.11]
1230.39 [1133.3, 1335.79] 0.1243 1047.56 [1019.81,
1076.05]
1266.6 [1148.62, 1396.69] ,.0001
IL-6 [pg/mL] 1.68 [1.55, 1.81] 2.26 [1.9, 2.69] 0.0045 1.83 [1.69, 1.97] 2.56 [1.95, 3.36] 0.0106
hsCRP [mg/L] 2.02 [1.86, 2.2] 2.61 [2.21, 3.08] 0.0251 1.85 [1.69, 2.02] 2.38 [1.86, 3.04] 0.0757
BMI [kg/m2] 27.65 [27.38, 27.92] 28.89 [28.13, 29.66] 0.0014 27.94 [27.57, 28.31] 29.73 [28.63, 30.88] 0.0047
Age [years] 62.87 [62.18, 63.58] 68.36 [66.66, 70.09] ,.0001 62.33 [61.63, 63.04] 66.88 [64.75, 69.09] 0.0002
Syst. BP [mmHg] 143.97 [142.65, 145.3] 150.13 [146.32, 154.05] 0.0013 139.79 [138.19, 141.4] 142.87 [138.53, 147.35] 0.2488
Glucose [mmol/l] 5.87 [5.78, 5.97] 6.33 [6.02, 6.67] 0.0008 5.62 [5.53, 5.7] 5.99 [5.66, 6.35] 0.0102
Cholesterol [mg/day] 5.29 [5.22, 5.36] 5.23 [5.05, 5.41] 0.531 5.63 [5.55, 5.71] 5.67 [5.4, 5.95] 0.7379
HDL [mmol/l] 1.23 [1.21, 1.25] 1.2 [1.15, 1.26] 0.3997 1.51 [1.48, 1.54] 1.51 [1.42, 1.61] 0.9586
Triglycerides[mmol/l] 1.77 [1.71, 1.85] 1.89 [1.72, 2.08] 0.2519 1.42 [1.37, 1.48] 1.48 [1.32, 1.66] 0.5051
TSH [mmol/l] 0.75 [0.71, 0.8] 0.82 [0.73, 0.92] 0.2876 0.75 [0.7, 0.81] 0.65 [0.49, 0.85] 0.1848
Alcohol [g/day] 1.48 [1.07, 2.05] 1.06 [0.44, 2.54] 0.4521 0.02 [0.01, 0.03] 0.04 [0.01, 0.12] 0.3864
Frequencies
Antiarrhythmic medication** 5 (0,6%) 1 (0,5%) 0.2187 4 (0,5%) 1 (1,3%) 0.3750
Antiphlogistic medication** 4 (0,5%) 1 (0,5) 0.3750 7 (1%) 1 (1,3%) 0.0703
QT prolonging medication ** 89 (11.2%) 25 (20.3%) 0.0042 82 (11.4%) 10 (13.3) 0.6103
Geometric means with respective 95% confidence intervals.
Abbreviation: cQT: Bazett corrected QT interval; sTNF-R1: Soluble tumor necrosis factor type 1; hsCRP: High-sensitive C-reactive protein; IL-6: Interleukin 6; BMI: Body
mass index; BP = Blood pressure; HDL: High density lipoprotein; TSH: Thyroid stimulating hormone.
* Proportion referred to the whole sample, ** Proportion within subgroup; {p-values refer to subgroups differences of subject with and without prolonged QT time
within sexes.
doi:10.1371/journal.pone.0095994.t001
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Cross-sectional association analysis
Using logistic regression models, sTNF-R1, but not hsCRP and
IL-6, had a considerable association with APQT in female
subjects. After adjustment for the considered covariates the odds
ratio (OR) in women was 1.89 (95% CI: 1.13–3.17) per 1,000 pg/
mL increase in sTNF-R1. In contrast, male subjects showed a
much lower estimate (0.74, 95% CI: 0.48–1.15), which was
accompanied by a considerable amount of uncertainty and was
not statistically significant. The interaction analysis supported our
finding of a circa 2.5-fold higher OR in women compared with
men (OR: 2.55, 95% CI: 1.30–5.02), suggesting a significantly
greater chance of APQT with increasing sTNF-R1 in women than
in men.
The estimated ORs of hsCRP and IL-6 appeared to reflect null
effects, which is contrary to sTNF-R1 in female subjects (Figures 1,
2). Additionally, the results indicated no relevant sex-dependent
association of hsCRP or IL-6 and APQT (Figures 1, 2).
Analyzing the QTc as a continuous metric variable in a linear
regression model adjusted for possible confounders we found again
an association of sTNF-R1 and QTc in women (5.75 ms/
Figure 1. Association of prolonged QTc time and inflammation parameters. Odds ratios (OR) with 95% confidence interval. Unadjusted
regression models of inflammation parameter. OR refers to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in
hsCRP.
doi:10.1371/journal.pone.0095994.g001
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1000 pg/mL, 95% CI: 1.32–10.18) but not in men (Table 2,
Figure 3). The estimated association of QTc and hsCRP in the
multiple analysis of both sexes was only minimal with wide
confidence intervals (2.17 ms/10 mg/L, 95% CI: —1.96–6.3 in
men; 2.02 ms/10 mg/L, 95% CI: 20.23–4.27 in women). In
contrast to sTNF-R1, the inflammation parameter of IL-6 was
negatively associated with QTc in women independently from
possible confounders (0.51 ms/10 pg/mL, 95% CI: 0.09–0.93). In
the separate analysis of HR and uncorrected QT time we found a
positive association of hsCRP with HR (3.24 s21/10 mg/L, 95%
CI: 1.28–5.2), and consequently a negative relation with the
uncorrected QT time in men. Interestingly, neither sTNF-R1 nor
IL-6 was associated with either HR or uncorrected QT time in
both sexes.
Sensitivity analysis
The exclusion of premenopausal women and women taking oral
hormones led to minor changes of the estimates, which were most
Figure 2. Association of prolonged QTc time and inflammation parameters. Odds ratios (OR) with 95% confidence interval. Models were
adjusted for age, anti-arrhythmic (ATC code: C01B) and anti-phlogistic medication (ATC code: A07), current smoking status, high density lipoprotein
(HDL), cholesterol, glucose blood level, alcohol intake, body mass index, thyroid stimulating hormone (TSH), systolic blood pressure and potentially
QT prolonging drugs (see www.qtdrugs.org). OR refers to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in
hsCRP.
doi:10.1371/journal.pone.0095994.g002
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relevant in the case of hsCRP where the covariate adjusted
association with QTc increased and became statistically significant
(see Table S1 and S2). Even more the negative association of IL-6
and QTc after covariate adjustment vanished, while the estimate
in the covariate adjusted analysis of sTNF-R1 and QTc increased
slightly.
After we excluded subjects with regular intake of potentially QT
prolonging drugs effect estimates were not relevantly altered, while
they increased slightly when the association of sTNF-R1 with QTc
in women was considered (see Table S3 and S4).
Discussion
Summarizing our results, sTNF-R1 seems to be more closely
associated with APQT in women than in men, while there was no
apparent association of hsCRP or IL-6 with QTc in both sexes. To
our knowledge we are the first study that has shown the association
of sTNF-R1 and prolonged QT time in women. Additionally,
hsCRP was associated with heart rate and thus the uncorrected
QT time rather than the actual heart rate corrected QT time.
Certain parameters (such as BMI, age) were higher in subjects with
APQT underlining their potential role as confounders in the case
of a simultaneous effect on exposure and outcome. Considering
Figure 3. Scatter plot of corrected QT time dependent on sTNF-R1. x-axis: Soluble tumor necrosis factor type 1 (sTNF-R1) in pg/mL; y-axis:
heart rate corrected QT time (QTc) in ms.
doi:10.1371/journal.pone.0095994.g003
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them as covariates enables us to present results independently from
a possibly confounding effect of these parameters (see also directed
acyclic graphs in Figure S1). The decrease of effect sizes after
covariate adjustment in our analyses might be in part explainable
by the presence of confounding in univariate regression models.
Furthermore, we observed a high number of prevalent cases
with APQT (11,6% of the entire cohort), which might be mainly
due to an equally high prevalence of hypertension and thus
ventricular hypertrophy in the CARLA cohort as it was shown
previously [34]. Using a QTc cut off of 480 ms Johnson et al.
found a prevalence of 13% in their collective of patients with
hypertrophic cardiomyopathy [35].
Previous studies reported a considerable relationship between
sTNF-R1 and cardiovascular diseases and, more specifically,
survival in patients with symptoms of chronic heart failure [6]. It is
well established that the TNF-alpha system is involved in the
pathophysiology and progression of heart failure [36,37]. Because
the shedding of sTNF-R1 from the membrane-bound domain
increases as the TNF-alpha system becomes more activated,
sTNF-R1 might reflect the activity of TNF-alpha [8,38]. A
prolongation of the QT interval has its electrophysiological
foundation in a prolonged action potential (AP) of myocardial
cells; thus we would expect an increase in AP due to TNF-alpha.
There is evidence from animal studies that TNF-alpha causes a
decreased expression of various potassium (K+) channels [11] and
a reduction in the density of cardiac transient outward K+ currents
(Ito) leading to an increase in AP duration. This mechanism was
mediated by the inducible nitric oxide synthase (iNOS) [12], which
was itself shown to be influenced by sex hormones (increased after
ovariectomy [39]). Furthermore, ion channels (including potassi-
um outward channels) of the human hearts have a different gene-
distribution in men and women, which might also include a
different susceptibility to TNF-alpha [40]. L-type Calcium
channels are a further potential reason for the observed TNF-
alpha relations. However, here the results are less conclusive:
Recently, it was found that TNF-alpha was associated with a
decrease in L-type Calcium currents, which would (contrary to our
findings) result in a shortened QT interval [9,10]. In contrast,
Duncan et al. [13] reported a Calcium leakage caused by TNF-
alpha provoking pro-arrhythmic events. A QT prolonging effect
might be triggered, but was not examined by the authors.
Summarizing previous experimental data K+ might play a key role
in the observed relations; however these data refer mostly to
animal studies rather than human beings. In line with our findings
sex differences in the association of sTNF-R1 with cardiovascular
events have been reported previously [41]. Interestingly, it was
shown in experimental studies that testosterone leads to a decrease
in TNF-alpha secretion in human macrophages. As we examined
a collective of elderly subects it is unlikely that female hormones
serve as an adverse contributor to the found relations in female
subjects. Reflecting experimental data the withdrawal of estradiol
was accompanied by an increase of TNF-alpha and iNOS [12]
expression in ovariectomized rats [42]. This might imply that sex
hormones in men and women have an inhibitory effect on the
association of TNF-alpha and QT time. In line with this, the
exclusion of premenopausal women or women with regular
hormone intake caused a minor increase in estimates. However,
this effect requires re-evaluation in a separate collective of younger
(premenopausal) females to estimate the effect of sex hormones
more reliable. In our cohort of the elderly population a direct
influence of sex hormones on the estimated effects is less likely.
Nevertheless, due to low case numbers in this subgroup we were
not able to provide convincing evidence of hormonal effects.
The finding of a negative association of IL-6 with QTc is
surprising as a positive association would be expected from
previous studies [43]. However, the effect was of low magnitude
and the statistical significance might be biased due to the low
variance of this parameter in women. Significantly higher levels of
CRP in AQPT subjects seem to be driven by the low variance of
this parameter rather than a relevant association with QT time,
which is underlined by the inconclusive results of regression
analyses. A similar explanation might also be true for CRP
underpinning that differences below 1 mg/L (and 1 pg/mL in the
case of IL-6) are also not relevant from a practical point of view.
Apart from the correlation with heart rate, CRP seems to play a
less important role in cardiac electrophysiology than the above-
Table 2. Linear regression of QTc, QT time and heart rate (HR) on sTNF-R1 in men and women (estimates with 95% confidence
interval).
QTc [ms] Men* [95% CI] Women*[95% CI] Men**[95% CI] Women**[95% CI]
sTNF-R1 [1000 pg/mL] 5.41 [2.52, 8.30] 8.46 [4.81, 12.11] 20.22 [23.44, 3] 5.75 [1.32, 10.18]
hsCRP [10 mg/L] 6.8 [2.68, 10.92] 2.94 [0.71, 5.18] 2.17 [21.96, 6.3] 2.02 [20.23, 4.27]
IL-6 [10 pg/mL] 20.11 [20.93, 0.7] 20.54 [20.96, 20.12] 20.2 [20.98, 0.59] 20.51 [20.93, 20.09]
QT [ms] Men* [95% CI] Women*[95% CI] Men**[95% CI] Women**[95% CI]
sTNF-R1 [1000 pg/mL] 6.13 [2.31, 9.95] 5.71 [0.88, 10.53] 1.54 [22.73, 5.82] 2.97 [22.86, 8.79]
hsCRP [10 mg/L] 25.98 [211.42, 20.54] 1.42 [21.45, 4.28] 28.36 [213.85, 22.87] 1.14 [21.77, 4.05]
IL-6 [10 pg/mL] 21.04 [22.11, 0.02] 20.01 [20.56, 0.54] 20.95 [21.99, 0.09] 0.01 [20.54, 0.56]
Heart Rate [s-1] Men* [95% CI] Women*[95% CI] Men**[95% CI] Women**[95% CI]
sTNF-R1 [1000 pg/mL] 21.36 [22.75, 0.02] 0.21 [21.41, 1.83] 21.36 [22.75, 0.02] 0.21 [21.41, 1.83]
hsCRP [10 mg/L] 3.24 [1.28, 5.2] 0.43 [20.51, 1.37] 3.24 [1.28, 5.2] 0.43 [20.51, 1.37]
IL-6 [10 pg/mL] 0.39 [0.02, 0.76] 20.11 [20.29, 0.07] 0.39 [0.02, 0.76] 20.11 [20.29, 0.07]
Estimates refer to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
*unadjusted values; ** covariate adjusted values: models were adjusted age, anti-arrhythmic (ATC code: C01B) and anti-phlogistic medication (ATC code: A07), current
smoking status, high density lipoprotein (HDL), cholesterol, glucose blood level, alcohol intake, body mass index, thyroid stimulating hormone (TSH), systolic blood
pressure and potentially QT prolonging drugs (see www.qtdrugs.org).
OR refers to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
doi:10.1371/journal.pone.0095994.t002
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mentioned sTNF-R1. In one of the few studies having examined
the association of inflammation and QT time effect sizes were
small [5], which emphasizes the vague role of hsCRP in cardiac
arrhythmia [44].
Limitations
As we only used cross-sectional data, we failed to clearly
determine the direction of the observed association, that is,
whether inflammation caused a prolonged QT time or a long QT
time led to higher blood levels of inflammation. At least for
hsCRP, Kim et al. [5] have argued that an effect of prolonged QT
time on inflammation is imaginable [45]. However, there is
humble evidence that inflammation, besides TNF-alpha, influenc-
es cardiac ion channels [13], atrial fibrillation [15] and heart rate
[46]. Future prospective studies with at least one follow-up might
provide deeper insights in the causality of inflammation and
prolonged QT time. The observational character of our study
makes it difficult to provide deeper insights into underlying
(patho)-physiologic mechanisms of our findings.
Furthermore, we only took three inflammation parameters into
account. As sTNF-R1 might be implicated in other inflammatory
mechanisms and related to a variety of other cytokines [47] further
studies are needed that examine a larger variety of possible
inflammation parameters. Due to the lack of genetic analyses we
were not able to report the effect of inflammation in subjects with
genetic anomalies related to a prolongation of QT time.
Respecting the collective of the CARLA study our results apply
mostly to the elderly population. Further studies with younger
(female) subjects are warranted in order to clarify the influence of
estrogens on QT time in more detail. Referring to our assumed
DAG model (see Figure S1); we are not able to estimate the direct
effect of inflammation on QT time (and vice versa) as electrolytes
which possibly mediate the effect of inflammation on QT time
were not measured in our study. However, it was our primary goal
to estimate the total effect of this relation, which is possible with
the used regression models [30–32].
In conclusion, our results underline the key role of the TNF-
alpha system represented by its receptor in cardiac control circuits.
Consequently, the effect of (anti-arrythmic) drugs on inflammation
and TNF receptors might appear to be an interesting future
research question [48,49].
Supporting Information
Figure S1 Directed acyclic graphs of parameters potentially
influencing the association of inflammation and QT time. Minimal
sufficient adjustment to estimate the total effect of inflammation of
corrected QT time: age, blood pressure, blood fats/cholesterol,
QT- prolonging drugs, smoking habit, and thyroid function.
Minimal sufficient adjustment to estimate the direct effect of
inflammation of corrected QT time: age, blood pressure, blood
fats/cholesterol, QT- prolonging drugs, smoking habit, thyroid
function, electrolytes.
(TIF)
Table S1 Linear regression of corrected QT time, QT time, and
heart rate on inflammation parameters in women after exclusion
of premenopausal women and women with regular hormone
intake (estimates with 95% confidence interval). Estimates refer to
a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-
6, and a 10 mg/L increase in hsCRP. *unadjusted; ** covariate
adjusted estimates: models were adjusted for age, anti-arrhythmic
(ATC code: C01B) and anti-phlogistic medication (ATC code:
A07), current smoking status, high density lipoprotein (HDL),
cholesterol, glucose blood level, alcohol intake, body mass index,
thyroid stimulating hormone (TSH), systolic blood pressure and
potentially QT prolonging drugs (see www.qtdrugs.org).
(DOCX)
Table S2 Logistic regression of APQT on inflammation
parameters in women after exclusion of premenopausal women
and women with regular hormone intake (odds ratio with 95%
confidence interval). Odds ratios refer to a 1,000 pg/mL increase
in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L
increase in hsCRP. *unadjusted Odds ratios; ** Odds ratios
adjusted for age, anti-arrhythmic (ATC code: C01B) and anti-
phlogistic medication (ATC code: A07), current smoking status,
high density lipoprotein (HDL), cholesterol, glucose blood level,
alcohol intake, body mass index, thyroid stimulating hormone
(TSH), systolic blood pressure and potentially QT prolonging
drugs (see www.qtdrugs.org). Abbreviation: APQT = abnormally
prolonged QT time.
(DOCX)
Table S3 Linear regression of corrected QT time, QT time, and
heart rate on inflammation parameters in men and women after
exclusion of subjects with regular intake of potentially QT
prolonging drugs (estimates with 95% confidence interval).
Estimates refer to a 1,000 pg/mL increase in sTNF-R1, a
10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
*unadjusted; ** covariate adjusted estimates: models were adjusted
for age, anti-arrhythmic (ATC code: C01B) and anti-phlogistic
medication (ATC code: A07), current smoking status, high density
lipoprotein (HDL), cholesterol, glucose blood level, alcohol intake,
body mass index, thyroid stimulating hormone (TSH), and systolic
blood pressure.
(DOCX)
Table S4 Logistic regression of APQT on inflammation
parameters in men and women after exclusion of subjects with
regular intake of potentially QT prolonging drugs (odds ratio with
95% confidence interval). Odds ratios refer to a 1,000 pg/mL
increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/
L increase in hsCRP. *unadjusted Odds ratios; ** Odds ratios
adjusted for age, anti-arrhythmic (ATC code: C01B) and anti-
phlogistic medication (ATC code: A07), current smoking status,
high density lipoprotein (HDL), cholesterol, glucose blood level,
alcohol intake, body mass index, thyroid stimulating hormone
(TSH), and systolic blood pressure. Abbreviation: APQT =
abnormally prolonged QT time.
(DOCX)
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